Literature DB >> 6305470

Cimetidine-resistant Zollinger-Ellison syndrome: successful management with ranitidine.

F M Habal, S J Soldin, G R Greenberg.   

Abstract

In a patient with the Zollinger-Ellison syndrome who had undergone vagotomy, pyloroplasty and, later, gastrojejunostomy, epigastric pain and stomal ulceration recurred despite the use of high doses (2700 mg/d) of cimetidine. Ranitidine, a new histamine H2-receptor antagonist, reversed all symptoms and healed the stomal ulcer without side effects, thus obviating the need for further surgery. Ranitidine may prove to be the drug of choice in the medical management of patients with the Zollinger-Ellison syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305470      PMCID: PMC1875089     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  11 in total

1.  H2-Histamine receptor blocking agents in the Zollinger-Ellison syndrome. Experience in seven cases and implications for long-term therapy.

Authors:  D M McCarthy; E J Olinger; R J May; B W Long; J D Gardner
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

Review 2.  Surgical management of the Zollinger-Ellison syndrome.

Authors:  P S Fox; J W Hofmann; S D Wilson; J J DeCosse
Journal:  Surg Clin North Am       Date:  1974-04       Impact factor: 2.741

3.  Analysis of ranitidine in serum by high performance liquid chromatography.

Authors:  H M Vandenberghe; S M MacLeod; W A Mahon; P A Lebert; S J Soldin
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

4.  The influence of total gastrectomy on survival in malignant Zollinger-Ellison tumors.

Authors:  P S Fox; J W Hofmann; J J Decosse; S D Wilson
Journal:  Ann Surg       Date:  1974-10       Impact factor: 12.969

5.  Ranitidine--a new H2-receptor antagonist.

Authors:  E P Woodings; G T Dixon; C Harrison; P Carey; D A Richards
Journal:  Gut       Date:  1980-03       Impact factor: 23.059

6.  Inhibition of gastric acid secretion in the dog by the H2-receptor antagonists, ranitidine, cimetidine, and metiamide.

Authors:  M J Daly; J M Humphray; R Stables
Journal:  Gut       Date:  1980-05       Impact factor: 23.059

7.  Is pancreatic polypeptide a marker for Zollinger-Ellison syndrome?

Authors:  I L Taylor; J H Walsh; J Rotter; E Passaro
Journal:  Lancet       Date:  1978-04-22       Impact factor: 79.321

8.  Effect of vagotomy in Zollinger-Ellison syndrome.

Authors:  C T Richardson; M Feldman; R N McClelland; R M Dickerman; D Kumpuris; J S Fordtran
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

9.  Ranitidine kinetics and dynamics. I. Oral dose studies.

Authors:  P A Lebert; S M MacLeod; W A Mahon; S J Soldin; H M Vandenberghe
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

10.  Cimetidine treatment of acute and chronic Zollinger-Ellison syndrome.

Authors:  S Bonfils; M Mignon; J Gratton
Journal:  World J Surg       Date:  1979-09-20       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.